Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Phase 1/2 Completed
55 enrolled 17 charts
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Phase 2 Completed
25 enrolled 14 charts
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Phase 2 Completed
94 enrolled 20 charts
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1/2 Completed
19 enrolled 12 charts
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
Phase 1/2 Completed
38 enrolled 17 charts
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
Phase 2 Completed
60 enrolled
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
Phase 1 Completed
34 enrolled
Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma
Phase 1 Completed
34 enrolled
Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma
Phase 1/2 Completed
74 enrolled 11 charts
Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Phase 2 Completed
68 enrolled
VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
Phase 1/2 Completed
42 enrolled 8 charts
Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma
Phase 2 Completed
50 enrolled
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
44 enrolled
V+DA-EPOCH-R
Phase 1 Completed
31 enrolled
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Phase 2 Completed
96 enrolled 11 charts
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Phase 2 Completed
11 enrolled
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Phase 2/3 Completed
361 enrolled 16 charts
Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients
Phase 1/2 Completed
54 enrolled 11 charts
Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
Phase 3 Completed
392 enrolled
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Phase NA Completed
174 enrolled 17 charts
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Phase 1/2 Completed
34 enrolled 22 charts
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Phase 3 Completed
397 enrolled 14 charts
SAHA
Phase 1 Completed
40 enrolled 13 charts
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Phase 2 Completed
473 enrolled 16 charts
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Phase 2 Completed
27 enrolled 13 charts
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
Phase 3 Completed
140 enrolled 15 charts
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Phase 1/2 Completed
76 enrolled 11 charts
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2/3 Completed
111 enrolled 20 charts
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Completed
25 enrolled
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
Phase 1 Completed
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Phase 2 Completed
16 enrolled 15 charts
CISL
Phase 2 Completed
75 enrolled
BME
Phase 2 Completed
51 enrolled
Combination Chemotherapy in Treating Patients With Lymphoma
Phase 3 Completed
116 enrolled
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
Phase 3 Completed
61 enrolled
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
Phase 2 Completed
35 enrolled
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
Phase 2 Completed
25 enrolled 8 charts
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Phase 2 Completed
27 enrolled 8 charts
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma
Phase 2 Completed
50 enrolled 12 charts
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
Phase 2 Completed
20 enrolled 9 charts
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Phase 2 Completed
213 enrolled
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
111 enrolled 11 charts
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Phase 2 Completed
48 enrolled 12 charts
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Phase 1/2 Completed
29 enrolled 10 charts
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
Phase 2 Completed
43 enrolled 5 charts
Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL
Phase 2 Completed
15 enrolled 3 charts
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1 Completed
16 enrolled
Tandem Auto-Allo Transplant for Lymphoma
Phase 2 Completed
42 enrolled 18 charts